Your browser doesn't support javascript.
loading
Racial Differences in the Presentation and Progression of Huntington's Disease.
Buchanan, Danielle A; Brown, Amy E; Osigwe, Elicia C; Pfalzer, Anna C; Mann, Leah G; Yan, Yan; Kang, Hakmook; Claassen, Daniel O.
Afiliação
  • Buchanan DA; Division of Cognitive and Behavioral Neurology, Department of Neurology, Vanderbilt University Medical Center, Nashville, Tennessee, USA.
  • Brown AE; Division of Cognitive and Behavioral Neurology, Department of Neurology, Vanderbilt University Medical Center, Nashville, Tennessee, USA.
  • Osigwe EC; Department of Neuroscience, Vanderbilt University, Nashville, Tennessee, USA.
  • Pfalzer AC; Division of Cognitive and Behavioral Neurology, Department of Neurology, Vanderbilt University Medical Center, Nashville, Tennessee, USA.
  • Mann LG; Department of Neuroscience, Vanderbilt University, Nashville, Tennessee, USA.
  • Yan Y; Department of Biostatistics, Vanderbilt University, Nashville, Tennessee, USA.
  • Kang H; Department of Biostatistics, Vanderbilt University, Nashville, Tennessee, USA.
  • Claassen DO; Division of Cognitive and Behavioral Neurology, Department of Neurology, Vanderbilt University Medical Center, Nashville, Tennessee, USA.
Mov Disord ; 38(10): 1945-1949, 2023 10.
Article em En | MEDLINE | ID: mdl-37559498
BACKGROUND: Huntington's disease (HD) is an autosomal dominant neurodegenerative disease that predominantly impacts a Caucasian population, but few efforts have explored racial differences in presentation and progression. OBJECTIVE: The aim was to assess the presentation and progression of HD across race groups using the Enroll-HD longitudinal observational study. METHODS: We applied propensity score matching for cytosine-adenine-guanine age product score, and age, to identify White, Hispanic, Asian, and Black participants from the Enroll-HD database. We compared clinical presentations at baseline, and progression over time, using White participants as a control cohort. RESULTS: Black participants were more severe at baseline across all clinical measures. No significant differences in progression were observed between race groups. CONCLUSIONS: We consider the factors driving clinical differences at baseline for Black participants. Our data emphasize the necessary improvement in underrepresented minority recruitment for studies of rare diseases. © 2023 International Parkinson and Movement Disorder Society.
Assuntos
Palavras-chave

Texto completo: 1 Coleções: 01-internacional Base de dados: MEDLINE Assunto principal: Doença de Huntington / Doenças Neurodegenerativas Tipo de estudo: Observational_studies / Prognostic_studies Limite: Humans Idioma: En Ano de publicação: 2023 Tipo de documento: Article

Texto completo: 1 Coleções: 01-internacional Base de dados: MEDLINE Assunto principal: Doença de Huntington / Doenças Neurodegenerativas Tipo de estudo: Observational_studies / Prognostic_studies Limite: Humans Idioma: En Ano de publicação: 2023 Tipo de documento: Article